Hutchmed's cancer drug FRUZAQLA® (fruquintinib) approved in Japan by Takeda Pharmaceutical.
HUTCHMED announced that its cancer drug FRUZAQLA® (fruquintinib) has been approved in Japan, with Takeda Pharmaceutical as the recipient of the approval. This marks a significant advancement in the treatment options available for cancer patients in Japan.
September 24, 2024
7 Articles